Gland Pharma faces a revenue growth hurdle in FY23; stock falls ...Middle East

The low margin syringes business was impacted by supply chain challenges and shutdown of two manufacturing lines in the domestic market

Hence then, the article about gland pharma faces a revenue growth hurdle in fy23 stock falls was published today ( Thursday 21/07/2022 - 06:12 PM ) and is available on Business Standard ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Gland Pharma faces a revenue growth hurdle in FY23; stock falls )

Also on site :

• StanChart: Bearish Oil Glut Narrative Fades as Brent Breaks $70
• Körber to acquire majority stake in Stellium to expand supply chain consulting capabilities
• iQIYI Reaches New Heights: 880 Invention Patents Filed in 2025, Over Half Driven by AI Innovation, Further Building Up Its AIGC Leadership